Examining quality of care for individuals treated for mental health using the HEDIS mental health quality measures

References

• Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62:593-602
   PubMed Web of Science ®Google Scholar
• Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder second edition. APA Pr Guidel [Internet] 2010. Available at: http://umh1946.edu.umh.es/wp-content/uploads/sites/172/2015/04/APA-Suicidal-Behaviors.pdf [Last accessed 20 April 2016]
   Google Scholar
• De Hert M, Schreurs V, Vancampfort D, et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009;8:15-22
   PubMed Web of Science ®Google Scholar
• Keck PE, McElroy SL, Strakowski SM, et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997;33:87-91
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Doshi JA. Continuity of care after inpatient discharge of patients with schizophrenia in the Medicaid program: a retrospective longitudinal cohort analysis. J Clin Psychiatry 2010;71:831-8
   PubMed Web of Science ®Google Scholar
• Opler LA, Caton CL, Shrout P, et al. Symptom profiles and homelessness in schizophrenia. J Nerv Ment Dis 1994;182:174-8
   PubMed Web of Science ®Google Scholar
• Onstad K, Khan A, Mierzejewski R, et al. Benchmarks for Medicaid adult health care quality measures: final report. Math Policy Res Natl Comm Qual Assur 2014;1-16
   Google Scholar
• NCQA. The State of Health Care Quality [Internet]. 2014. Available at: https://store.ncqa.org/index.php/catalog/product/view/id/1865
   Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31
   PubMed Web of Science ®Google Scholar
• Treuer T, Hoffmann VP, Chen AK-P, et al. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry 2009;10:729-40
   PubMed Web of Science ®Google Scholar
• Anderson TR, Goldberg JF, Harrow M. A review of medication side effects and treatment adherence in bipolar disorder. Prim Psychiatry 2004;11:48-54
   Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
   PubMed Web of Science ®Google Scholar
• Malhotra N, Kulhara P, Chakrabarti S, et al. A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia. J Affect Disord 2013;150:653-8
   PubMed Web of Science ®Google Scholar
• Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol 2013;3:33-51
   PubMedGoogle Scholar
• Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015;14:339-47
   PubMed Web of Science ®Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63
   PubMed Web of Science ®Google Scholar
• Gilmer T, Dolder C, Lacro J, et al. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficieries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar
• Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004;30:255
   Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-7
   PubMed Web of Science ®Google Scholar
• Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the “revolving door” phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-61
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord 2013;148:161-9
   PubMed Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 2013;3:200-18
   PubMedGoogle Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014;5:43-62
   PubMedGoogle Scholar
• Archer and Marmor on Medicare versus commercial insurance - PNHP’s Official Blog [Internet]. Available at: http://pnhp.org/blog/2012/02/16/archer-and-marmor-on-medicare-versus-commercial-insurance/ [Last accessed 26 February 2018]
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Ladha KS, Zhao K, Quraishi SA, et al. The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients. BMJ Open [Internet]. 2015;5. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563218/ [Last accessed 5 December 2017]
   Web of Science ®Google Scholar
• Ranstam J. Why the P-value culture is bad and confidence intervals a better alternative. Osteoarthritis Cartilage 2012;20:805-8
   PubMed Web of Science ®Google Scholar
• Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol 2016;31:337-50
   PubMed Web of Science ®Google Scholar
• Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007;15:245-58
   PubMed Web of Science ®Google Scholar
• Bressington D, Mui J, Tse ML, et al. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study. BMC Psychiatry [Internet] 2016;16. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116189/ [Last accessed 30 November 2017]
   Web of Science ®Google Scholar
• Phillips LS, Ratner RE, Buse JB, et al. We can change the natural history of type 2 diabetes. Diabetes Care 2014;37:2668-76
   PubMed Web of Science ®Google Scholar
• Zhang P-Y. Cardiovascular disease in diabetes. Eur Rev Med Pharmacol Sci 2014;18:2205-14
   PubMed Web of Science ®Google Scholar
• Velligan DI, Lam Y-WF, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006;32:724-42
   PubMed Web of Science ®Google Scholar
• Lang K, Federico V, Muser E, et al. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia. J Med Econ 2013;16:997-1006
   PubMedGoogle Scholar
• Stephenson JJ, Tunceli O, Tuncelli O, et al. Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims. Int J Clin Pract 2012;66:565-73
   PubMed Web of Science ®Google Scholar
• Acosta FJ, Ramallo-Fariña Y, Bosch E, et al. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®). Schizophr Res 2013;146:196-200
   PubMed Web of Science ®Google Scholar
• Acosta FJ, Hernández JL, Pereira J, et al. Medication adherence in schizophrenia. World J Psychiatry 2012;2:74-82
   PubMedGoogle Scholar
• Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005;133:129-33
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. J Psychiatr Pract 2010;16:34-45
   PubMed Web of Science ®Google Scholar
• Valenstein M, McCarthy JF, Ganoczy D, et al. Assertive community treatment in veterans’ affairs settings: impact on adherence to antipsychotic medication. Psychiatr Serv Wash DC 2013;64:445-451, 451.e1
   PubMed Web of Science ®Google Scholar
• Marcus SC, Chuang C-C, Ng-Mak DS, et al. Outpatient follow-up care and risk of hospital readmission in schizophrenia and bipolar disorder. Psychiatr Serv Wash DC 2017;68:1239-46
   PubMed Web of Science ®Google Scholar
• Hirschfeld R. Bipolar depression: the real challenge. Eur Neuropsychopharmacol 2004;14:S83-8
   PubMed Web of Science ®Google Scholar
• Makaryus AN, Friedman EA. Patients’ understanding of their treatment plans and diagnosis at discharge. Mayo Clin Proc 2005;80:991-4
   PubMed Web of Science ®Google Scholar
• Bauer MS, McBride L, Williford WO, et al. Collaborative care for bipolar disorder: Part II. Impact on clinical outcome, function, and costs. Psychiatr Serv Wash DC 2006;57:937-45
   PubMed Web of Science ®Google Scholar